We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Strange Chimeras Defy Scientific Understanding of Human Genetics

By LabMedica International staff writers
Posted on 18 Oct 2016
Print article
Image: A diagram of mechanisms of RNA-Mediated DNA Rearrangement. (A) Chimeric RNAs act as repair templates for double-strand DNA breakage. (B) Chimeric RNAs act as scaffolds to bring two genomic loci into proximity, which might promote breakage and fusion between the two gene loci (Photo courtesy of the University of Virginia).
Image: A diagram of mechanisms of RNA-Mediated DNA Rearrangement. (A) Chimeric RNAs act as repair templates for double-strand DNA breakage. (B) Chimeric RNAs act as scaffolds to bring two genomic loci into proximity, which might promote breakage and fusion between the two gene loci (Photo courtesy of the University of Virginia).
The human genome is far more complex than thought, with genes functioning in an unexpected fashion that scientists have wrongly assumed must indicate cancer as gene fusions and their encoded products fusion ribonucleic acids (RNAs) and proteins are viewed as one of the hallmarks of cancer.

Traditionally, gene fusions were thought to be generated solely by chromosomal rearrangements. However, recent discoveries of trans-splicing and cis-splicing events between neighboring genes suggest that there are other mechanisms to generate chimeric fusion RNAs without corresponding changes in DNA.

Scientists at the University of Virginia (Charlottesville, VA, USA) have reviewed the emerging field that is challenging fundamental assumptions about human genetics. They seek to understand what is called chimeric RNA, genetic material that results when genes on two different chromosomes produce "fusion" RNA in a way scientists say should not happen. Scientists have traditionally assumed these chimeric RNA are signs of cancer, of something gone wrong in the genetic transcription process, but the investigators work shows that's not always the case. Instead, these strange fusions can also be a normal, functional part of our genetic programming.

In addition, chimeric RNAs have been detected in normal physiology, complicating the use of fusions in cancer detection and therapy. By contrast, ‘intergenically spliced’ fusion RNAs represents a new repertoire of biomarkers and therapeutic targets. The team reviewed the current knowledge on chimeric RNAs and implications for cancer detection and treatment, and discusses outstanding questions for the advancement of the field.

Hui Li, PhD, an associate professor of Pathology and senior author of the study, said, “This is the main concept we want to let the field of cancer biology know: this kind of thing exists in normal physiology. It's not cancer specific. There's a danger to assuming everything is cancer. That's actually dangerous. Don't rush to judgment about all of these chimeras you find in cancer cells, because they could occur in normal cells.”

Because these natural chimeras were discovered so recently, relatively little is known about them. Professor Li and his fellow scientists have shown that they occur when the instructions in our DNA are being carried out by RNA inside our cells. But the scientists can't say how the fusions occur or why they occur or exactly how frequently they occur. And that speaks to how much there is to learn. To build a foundation for discovery, Professor Li is creating a database of naturally occurring fusions, to help sort normal chimeras from ones that might be signs of cancer The study was published in the September 2016 issue of the journal Trends in Cancer.

Related Links:
University of Virginia

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.